About Us

Greenshift Labs was founded in early 2019 with the aim to develop advanced, simple to use products that promote cleaner and healthier living. The company draws upon the expertise of an international team of biologists, chemists, and business-development professionals with the goal to develop scientific solutions in healthcare and wellbeing with competitive advantage and commercial potential. The company is registered in Germany with offices in Berlin and a laboratory at the Science Park in Potsdam. Following intensive research work, we decided to focus on developing applications for antimicrobial and antiviral coatings.

Since this is a broad field that enables the development of countless applications, we chose to focus in the near future on the development of two product series of significant business potential:

The BioShield Series:

The company developed BioShield, an antimicrobial solution based on natural ingredients, safe for human touch and for usage with food. Tests by an independent laboratory in Germany showed excellent results in terms of antimicrobial efficacy (log 3.49).

The company completed the development of B-Armor, an application for coating hard surfaces, and is in the early stages of developing an applications that will enable the production of antimicrobial paper and fabric. Later, additional applications will be developed based on the same active ingredients.

The EverShield Series:

A patented phosphorus-salt-based polymer that remains effective for about 50 years and is more efficient than technologies currently available in the antipathogenic coating market. The applications that the company plans to develop are intended for the food industry, hospitals, public transportation, aircraft, and similar industries. The coating is both antimicrobial and antiviral.

Humanity Is Under Attack

As humanity progresses, more and more people move to crowded cities. The world becomes more technological; we perform more actions using smart cards and touchscreens, shopping and recreational centers, food chains, airports, and more. These confined, air-conditioned spaces, become bigger and more common, and are built to hold ever-increasing amounts of people.

In December 2019 the international media started reporting about a disease that broke out in Wuhan, China. By February 2020 the epidemic’s focal point started shifting to other countries. During March the number of infections started to increase rapidly, spreading to more than 150 countries, mainly in Europe. The disease, spreading rapidly around the world, has infected tens of millions of people and the death of nearly 2 million, accompanied by a severe economic crisis.

Humanity was shocked. The pandemic’s implications struck all of us within weeks. Suddenly, the much repeated script of dozens of apocalyptic movies turned to reality.

It was a terrible blow, but a closer look reveals a much more disconcerting picture. During the past 18 years the world has experienced a considerable number of lethal viral epidemics.

Between 2002-2004 a pandemic caused by SARS-CoV-1- a close relative of the SARS-CoV-2 that caused the current pandemic, caused the SARS pandemic. Over 8,000 people from 29 different countries and territories were infected, and at least 774 died worldwide. The major part of the outbreak lasted about 8 months.

The virus was lethal in around 10% of the cases. As of 2021, there is no cure or protective vaccine for SARS that has been shown to be both safe and effective in humans.

Between 2006-2008 dozens of outbreaks of H5N1, known as avian influenza or “bird flu” were reported worldwide. As of May 2020, the WHO reported a total of 861 confirmed human cases which resulted in the deaths of 455 people since 2003. That is more than 50%!

In 2009 swine flu, an influenza pandemic, hit the world. Some studies estimated that the actual number of cases including asymptomatic and mild cases could be 700 million to 1.4 billion people – 11-21% of the global population of 6.8 billion at the time. The lower value of 700 million is more than the 500 million people estimated to have been infected by the Spanish flu pandemic. The number of lab-confirmed deaths reported to the World Health Organization (WHO) is 18,449.

From 1976 to 2012 the World Health Organization has reported 24 outbreaks of Ebola. The disease has a high risk of death, killing 25% to 90% of those infected, with an average of about 50%. The largest outbreak to date was the epidemic in West Africa, which occurred from December 2013 to January 2016, with 28,646 cases and 11,323 deaths. Other outbreaks in Africa took place in 2017 and 2018.

How were the outbreaks thwarted?

1. SARS disappeared the same as it appeared: immediately and without human intervention. After it vanished, the efforts to find a vaccine were halted.

2. In the end of 2005 the last cases of the avian flu were detected. Until now no vaccine has been developed. Research has shown that a highly contagious strain of H5N1, one that might allow airborne transmission between mammals, can be reached in only a few mutations.

3. The swine flu lasted until August 2010. Until now no vaccine has been developed.

4. Efforts to develop a vaccine to Ebola have started already on 1976, but only on December 2019 did the FDA approve a vaccine by Merck.

The virus’s high infectiousness and lethality, as well as the disease’s short incubation time, are the main factors that limit Ebola outbreaks and prevent them from turning into pandemics. Carriers often die before they get a chance to spread the virus, rendering Ebola a “self-destructing disease”. That said, it cannot be guaranteed that the virus does not develop mutations that will completely alter the infection pattern.

5. In November 2020 Pfizer, Moderna, and AstraZeneca announced the development of Covid-19 vaccines. The world sighed in relief.

In December 2020 a new coronavirus variant was found in Britain, carrying 17 mutations compared to the known virus. The mutations might enable faster spread. Ten days later the British Minister of Health announced two cases of an additional mutated strains. According to him, the new mutation is more infection than the one found before.

Disregarding the fact that on average every 11 days a new variant of the virus emerges, it took humanity a whole year to develop a vaccine. Who can guarantee that next time the process will not last 5 years? The HIV virus, the causative agent of AIDS, was first detected in 1981, and according to estimates by the World Health Organization it claimed the lives of some 36 million people by the end of 2012. After all these years and despite endless budgets invested in trying to find a cure or a vaccine, the disease is still incurable. Who can guarantee that the next virus will not be contagious like the swine flu and deadly like Ebola? Who knows if the next virus will not completely paralyze the world economy for periods of time that will not allow recovery?

Analysis of outbreaks in the past two decades shows that a new outbreak is only a matter of time. Decision makers therefore already understand that the right solution is not to find a vaccine or a cure but to reduce the ability of viruses to spread. With this in mind, Greenshift Labs is well positioned, since it offers a wide variety of antimicrobial products at advanced stages of development, products based on various technologies and application modes.

Our Team

Dr. Arren Bar-Even

Obtained a B.Sc. from the excellence program of the Technion – Israel Institute of Technology. He did his M.Sc. in Bioinformatics at the Weizmann Institute of Science. He spent several years in the biotech industry before returning to academia to complete a Ph.D. in Biochemistry at the Weizmann Institute of Science, specializing in the design principles of cellular metabolism. Since 2015, he serves as the head of the Systems and Synthetic Metabolism lab at the Max Planck Institute of Molecular Plant Physiology (Potsdam, Germany), studying the biochemical logic of metabolic pathways and their applications for the design and implementation of metabolic designs that addresses humanity’s needs in food, chemical, and energy production. He published in top journals, including Cell, Nature Genetics, Nature Chemical Biology, Nature Catalysis, and the Proceedings of the National Academy of Sciences.

Dr. Ryan Guterman

A synthetic and polymer chemist with over 10 years of experience. He acquired his Ph.D. in 2015 at Western University (London, Canada) before moving to Germany to work at the Max Planck Institute of Colloids and Interfaces (Potsdam, Germany) where he currently runs his own lab. His work can be described as a combination of fundamental discovery and targeted technological application ranging from energy devices to proteomics. He has worked alongside industry and academic partners in two continents and participated in large European research consortia. With over 10 years of experience in designing polymer coatings and antimicrobial substances, he focuses on bottom-up solutions to pressing problems in healthcare. In this way, he seeks to accelerate the process of applying new discoveries to real-world technologies. He published in top journals, including Nature Communications and Angewandte Chemie.

Dr. Hezi Tenenboim

A long-time resident of Germany, completed his B.Sc. in Biology at the University of Applied Science Bonn-Rhein-Sieg, and his M.Sc. in Life Sciences at the University of Tübingen. He obtained his Ph.D. studies at the Max Planck Institute of Molecular Plant Physiology (Potsdam), studying plant and bacterial physiology and genetics. He worked in three different Max Planck Institutes in Germany, including MPI for Infection Biology in Berlin. He published scientific articles in top journals, including Cell and Nature Structural and Molecular Biology. Hezi serves as the company’s CEO and Scientific Coordinator.

Technology and Products

Greenshift Labs focuses on the creation of novel antibacterial and antiviral coatings that are safe, effective, and green. Two product categories are currently being developed that fill their respective niches in the coatings market and address specific problems currently plaguing the antibacterial coatings field. They include the BioShield SeriesGreenshift Labs’ Antimicrobial Natural Series; a product line designed for the general public that harnesses completely natural and safe antimicrobials, and the EverShield Seriesa long-lasting coating designed to withstand the scratches and scuffs of life. These two series are non-overlapping and together cover the most important territory for antimicrobial coatings.

1. BioShield Series – Natural antimicrobial coating solutions

The vast majority of antimicrobial products on the market today are often harmful, irritating, or do not easily biodegrade in the environment. Many of these substances, including quaternary ammonium salts (Lysol wipes), bleach-containing (Clorox), and silver-containing (Microban) products, are decades-old solutions to the problems associated with bacterial contamination and were implemented in the previous century when their effect on human or environmental health was not a concern. In recent years however, society has become profoundly aware of how such products can affect health, which has led to more stringent consumer decisions that demand performance and safety for themselves and the environment. We believe the solution to this problem is to harness what nature provides us and combine it with state-of-the-art research to design a product made for the 21st century; a product that is both effective and safe for humans and the environment.

Greenshift Labs has created a new product line that offers antimicrobial protection and safety for consumers to use in their daily lives. The key to our approach begins with an inexpensive, natural and food-safe substances. We then process these substances using novel methods developed in our labs to introduce antimicrobial function and combine it with delivery agents to produce our product. We call this new product BioShield. When applied to a surface, BioShield dries within seconds, kills bacteria and leaves a thin transparent coating that prolongs the antimicrobial effect.

An independent lab’s tests of BioShield coatings has found that they kill at least 99.97% of E. coli and S. aureus and last on surfaces for at least 30 days.

Based on these findings, the company is developing three different applications:

B-Armor – Natural antimicrobial coating solution for everyday touch surfaces

Antimicrobial protection for hard surfaces in your daily life. The product is applied using a wet wipe or sprayed from a bottle and left to dry after application and drying, surfaces are coated in a thin, optically clear antimicrobial coating. Using a wet wipe, the surface is cleaned of dirt and grease while also eliminating any bacteria. The coating provides protection for about a month and is completely safe to touch.

The company filed a provisional application in the US for the product and the technology in which it operates.

We estimate that within 6 months of development we will improve the formulation to be both antiviral and more durable.

The company is currently conducting initial negotiations with several wipe manufacturers, including Al Bad, Israel’s biggest wipe producer and number 3 worldwide, and Dynamic Wipe Industries, Israel’s second largest wipe producer, with the aim of adapting the solution for usage with wipes. It currently appears that marketing and distribution will be based on the chosen manufacturer’s mechanisms.

PaperShield Natural antimicrobial coating solution for the paper industry

Our active ingredient can be incorporated into any number of formulations, including those for the paper industry. Because PaperShield is a safe and natural antimicrobial, it is ideal to be used with paper that comes into contact with food.

Paper is a natural product used in the food sector for everything from single-use food wrappers and tray covers to packaging and napkins. The introduction of PaperShield to paper in these products can inhibit bacterial proliferation and reduce the chance of infection because of contamination. Our active ingredients are simple to prepare on a large scale and will allow the company to penetrate a market with a yearly worth of billions of dollars.

All our competitors use identical, obsolete silver-based technology. Though effective, this technology is not environmentally friendly, not sustainable, and is more expensive than PaperShield. This makes usage of silver in food packaging unlikely, leaving us as the sole player in the fast-food and bakery market.

FabricShield Natural antimicrobial coating solution for fabrics

Studies have concluded that 7–9% of hospital deaths are due to infections and complications traced to microbial exposure at a medical facility. For this reason, surface sterility and the personal hygiene of medical staff are of crucial importance in maintaining patient safety.

Touch surfaces like elevator buttons, railings, and medical equipment are among the most common vectors for infection, however fabrics found in curtains and uniforms are more difficult to keep clean and free of pathogens. FabricShield offers a solution to this problem thanks to its safety, ease of application, and ability to exterminate bacteria. It is also safe for most fabrics and skin contact, making it an ideal option.

2. EverShield Series – long-lasting antimicrobial coating for rigid surfaces

The EverShield Series coating is based on phosphonium ion technology combined with UV-curing. This unique combination offers an unprecedented coating design that is robust, easy to apply, and effective at killing pathogens like no other.The polymer remains effective for decades and is more resistant to abrasion than current technologies on the market.

Greenshift Labs will develop applications for a variety of areas, including food producers, hospitals, public transport, aircraft, airports, malls, and more.

Long-lasting coatings that kill pathogens are uniquely suited for these industries, among many others where touch-surfaces pose a public health risk. Our EverShieldSeries directly targets these industries by offering excellent protection, simple coating procedures, and performance all in one. Tests performed have shown that this polymer provides greater than log 3 protection level and is easy to apply to any surface. The use of phosphonium in contrast to ammonium-based salts, provides a much greater potential in antimicrobial activity which has yet to be relegalized. This development will allow the company to launch a leading product through which it will dominate the hospital protection market. Along with these properties, the said polymer is inexpensive to manufacture and significantly more durable than its silver- and copper-based competitors. The reason our competitors do not use phosphorus salts is that developing applications for this polymer requires specific expertise that they lack.

Commercial potential

BioShield Series

The surprise and upheaval we experienced following the onset of the pandemic caused rapid changes in our behavior and increased awareness of everything related to closeness and touch, requiring us to think in terms of clean/contaminated, safe/potentially contagious.

It’s hard to believe, but recent tests show that our cellphones are three times more contaminated than the public toilet. It is doubtful if any of us are willing to put our faces on the toilet, yet we do such a thing with our cellphones while eating or interacting with children.

It’s not just the cellphone. The computer keyboard and mouse, the office door handle, the steering wheel of our car, and hundreds of other surfaces with which we come into constant contact—all of them are contaminated and contribute to the spread of infection. As people become more aware of this fact, steps are being taken to ensure our touch surfaces are kept clean for prolonged periods, which can be achieved with coatings developed by Greenshift Labs.

Materials like fabric and paper also pose significant risk to spread infection when touched or when in contact with food. In addition to wipe-based products, the antimicrobial substance we have developed can be incorporated into many types of woven fabrics and paper to imbue them with the desired antimicrobial protection. The ability to do so in a safe and cost effective manner opens up a potential market worth billions. Moreover, as mentioned before, between 7–9% of hospital deaths are due to hospital-acquired infections and complications related to both hard surfaces and fabrics. Therefore, surface sterility and the personal hygiene of medical staff are of crucial importance in maintaining patient safety. We believe that in light of the proven effectiveness of our solution and in light of its natural ingredients that are safe for constant contact with human skin, its suitability for protecting separation curtains and medical staff uniforms embodies significant revenue potential.

EverShield Series

Protection against pathogens has shifted from an abstract recommendation into a binding necessity. Businesses that do not act in accordance with it will be defeated by their competitors and eventually lose their ability to survive.

At this point we can conclude with certainty that entire industries will be forced to change the way they operate in order to reduce their customers’ concerns of becoming sick. In fact, we are confident that most businesses in developed countries have already begun to prepare for a fundamental and long-term change in the way their services are provided to their customers and that this trend will only intensify over the next two years.

We believe that our patented products will be the best in their class and provide new solutions to industries seeking improved performance and safety.

Market size and characteristics

Market analysis conducted for 2019 estimated the size of the global antimicrobial coatings market at approximately USD 7.1 B. According to this analysis, the complex annual growth rate (CAGR) from 2020 to 2027 is expected to stand at 12.8%.

Growth in this market is driven by factors such as increasing awareness of antimicrobial coatings, growth in initiatives and funding from government and private organizations to develop antimicrobial coatings, as well as an increase in the number of cases of infections from contaminated food.

Since the outbreak of the pandemic, there has been a significant increase in demand for disinfectant products and materials. This increase also drives the demand for antimicrobial coating products, with more recent analyses already indicating that the market size in 2020 will reach USD 8.1 B.

These figures, based on consumption in the Western world, are to be supplemented by data from emerging economies in Latin America, Southeast Asia and Africa, where there has hitherto been low awareness of antimicrobial coatings and which now provide significant business opportunities for players operating in this market.

Contact Us

Main office:
Oldenburger Strasse 6
10551 Berlin

Am Mühlenberg 11
14476 Potsdam

+49 176 830 94 838

Potsdam Science Park

Please fill in your details at the form or send us an email: